CD BioGlyco has constructed a Vaccine Research and Development Platform and has long been committed to the development of various vaccines and the production of related antigens. Among them, GXM has a significant recognition effect on certain monoclonal antibodies, while GXM-protein conjugated vaccines can trigger protective immune responses. Therefore, we provide not only the production of GXM but also the immunization study of GXM and the development service of related vaccines.
We synthesize the target antigen by using a specific glycoside as a substrate for coupling with the pentasaccharide receptor, through a process of glycosylation, protection-deprotection, and concomitant reduction of the azide group to form the amino group required for subsequent coupling to the protein. During this process, the target antigen is isolated, purified, and structurally analyzed using nuclear magnetic resonance (NMR) and chromatographic techniques.
Given the importance of podocarp polysaccharides in virulence and the preference for polysaccharide-based vaccines for encapsulated bacterial pathogens, we inject the GXM antibody into a mouse infection model to probe the immune response. In this process, the coupling of C. neoformans podoplanar polysaccharides to proteins produces highly immunogenic compounds that can trigger high antibody responses.
Based on the results of the immune response tests, we will develop an antifungal vaccine consisting of a podoplanar polysaccharide-protein complex that will be highly immunogenic.
Fig.1 We offer a full portfolio from antigen production to vaccine development. (CD BioGlyco)
Technology: Development of antifungal-type vaccines using immunogenic oligosaccharides with GXM structural motifs.
Journal: Vaccine
IF: 5.5
Published: 2005
Result: The first synthetic oligosaccharide vaccine against a fungal pathogen is reported. The vaccine was shown to be immunogenic in mice, although the antibodies induced appear to be qualitatively different from those induced by GXM-derived immunogens. The ability to synthesize immunogenic GXM hepta-oligosaccharide motifs will provide new strategies for anti-epitope recognition of monoclonal antibodies and vaccine design.
Fig.2 Indirect immunofluorescence showing reactivity of immune serum with C. neoformans strains 24067 (serotype D) and NIH 3939 (Serotype B). (Oscarson, et al., 2005)
CD BioGlyco has specialized knowledge and extensive experience in the field of antigen production and vaccine development. We not only provide our clients with the production of antigens but also vaccine development. Our team is knowledgeable and capable of meeting your requirements. If you are interested in our services, please feel free to contact us for more details.
Reference
